本拉利祖马布会影响严重喘患者NK细胞的成熟和增殖
Laura Bergantini1, Miriana d'Alessandro1, Tommaso Pianigiani1
1Respiratory Disease Unit, Department of Medical Sciences, University Hospital of Siena (Azienda Ospedaliera Universitaria Senese, AOUS), Viale Bracci, 53100 Siena, Italy.
Clinical immunology (Orlando, Fla.)
|June 28, 2023
概括
在严重喘患者中,本拉利祖马布治疗促进自然杀手 (NK) 细胞的成熟. 这种NK细胞表型的转变与功能参数的改善和降低类固醇依赖性有关.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝纳利祖马布通过其非化恒定片段向自然杀手 (NK) 细胞上的CD16a受体.
- 严重喘的特点是特定的免疫细胞配置,可以通过向治疗来调节.
研究的目的:
- 分析本拉利祖马布治疗前后严重喘患者自然杀手 (NK) 和T细胞子集的变化.
- 为了研究本拉利祖马布在严重喘中的作用机制.
主要方法:
- 使用多参数流细胞计检测NK和T细胞子集.
- 使用多重测定测量血清细胞因子水平.
- 在后续样本上进行了功能性扩散测试.
主要成果:
- 严重喘患者在基线与健康对照人群相比,表现出较高比例的未成熟NK细胞.
- 本拉利祖马布的使用诱导了NK细胞的增殖,激活和转向成熟的表型.
- 观察到NK细胞变化,功能参数和类固醇节约作用之间的相关性.
结论:
- 贝纳利祖马布治疗调节严重喘的NK细胞群,促进成熟.
- 这些发现增强了对本拉利祖马布在严重喘中解决炎症的机制的理解.
关键词:
ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC ADCC is also known as ADCC ADCC ADCC is also known as ADCC贝纳利兹马巴姆 (Benralizumab) 是一个在CD137中,CD137中,CD137中,CD137中在 NK 细胞中,NK 细胞是 NK 细胞.严重的喘患者.相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357
Antiasthma Drugs: Leukotriene Modifiers
371
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
371
Antiasthma Drugs: β2-Adrenoceptor Agonists
317
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
317
Asthma: Pathogenesis and Management
458
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
458
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K


